-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Acutus Medical, Inc. (NASDAQ:AFIB) Sees Large Decline in Short Interest
Acutus Medical, Inc. (NASDAQ:AFIB) Sees Large Decline in Short Interest
Acutus Medical, Inc. (NASDAQ:AFIB – Get Rating) was the recipient of a significant decline in short interest during the month of December. As of December 30th, there was short interest totalling 899,000 shares, a decline of 15.2% from the December 15th total of 1,060,000 shares. Based on an average daily volume of 547,500 shares, the short-interest ratio is presently 1.6 days. Approximately 4.7% of the shares of the stock are short sold.
Institutional Investors Weigh In On Acutus Medical
Institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. increased its holdings in shares of Acutus Medical by 70.1% in the 3rd quarter. Vanguard Group Inc. now owns 1,142,170 shares of the company's stock valued at $1,005,000 after purchasing an additional 470,719 shares during the period. State Street Corp increased its holdings in shares of Acutus Medical by 11.0% in the 1st quarter. State Street Corp now owns 430,865 shares of the company's stock valued at $599,000 after purchasing an additional 42,578 shares during the period. Renaissance Technologies LLC acquired a new position in shares of Acutus Medical in the 1st quarter valued at about $499,000. AQR Capital Management LLC increased its holdings in Acutus Medical by 844.0% in the second quarter. AQR Capital Management LLC now owns 174,352 shares of the company's stock worth $195,000 after buying an additional 155,883 shares during the last quarter. Finally, Mirabella Financial Services LLP acquired a new position in Acutus Medical in the first quarter worth approximately $48,000. 36.32% of the stock is owned by institutional investors and hedge funds.
Get Acutus Medical alerts:Acutus Medical Stock Up 15.4 %
Shares of NASDAQ:AFIB opened at $1.50 on Friday. Acutus Medical has a 1 year low of $0.48 and a 1 year high of $2.49. The company has a market cap of $42.68 million, a PE ratio of -0.48 and a beta of 0.64. The company has a debt-to-equity ratio of 0.59, a current ratio of 5.12 and a quick ratio of 4.33. The stock's 50-day moving average is $0.98 and its 200 day moving average is $1.05.
Acutus Medical (NASDAQ:AFIB – Get Rating) last released its quarterly earnings data on Thursday, November 10th. The company reported ($0.72) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.11. The business had revenue of $3.64 million for the quarter, compared to analysts' expectations of $3.52 million. Acutus Medical had a negative return on equity of 100.62% and a negative net margin of 545.51%. Sell-side analysts anticipate that Acutus Medical will post -2.84 EPS for the current year.About Acutus Medical
(Get Rating)
Acutus Medical, Inc, an arrhythmia management company, designs, manufactures, and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. The company's product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact force ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs.
Read More
- Get a free copy of the StockNews.com research report on Acutus Medical (AFIB)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
Receive News & Ratings for Acutus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acutus Medical and related companies with MarketBeat.com's FREE daily email newsletter.
Acutus Medical,Inc.(纳斯达克代码:AFIB-GET评级)是空头股数12月份股价大幅下跌的接受者。截至12月30日,空头股数共有89.9万股,与12月15日的106万股相比,下降了15.2%。以日均成交量54.75万股计算,目前短息比率为1.6天。大约4.7%的股票被卖空。
机构投资者看好Acutus Medical
机构投资者和对冲基金最近买卖了该公司的股票。先锋集团第三季度增持Acutus Medical股票70.1%。先锋集团目前持有1,142,170股该公司股票,价值1,005,000美元,在此期间又购买了470,719股。道富集团在第一季度增持了Acutus Medical的股票11.0%。道富银行目前持有430,865股该公司股票,价值599,000美元,在此期间又购买了42,578股。复兴科技有限责任公司在第一季度收购了Acutus Medical的新头寸,价值约49.9万美元。AQR资本管理有限责任公司在第二季度增持了Acutus Medical的股份844.0%。AQR Capital Management LLC现在拥有174,352股该公司股票,价值19.5万美元,上个季度又购买了155,883股。最后,Mirabella Financial Services LLP在第一季度收购了Acutus Medical的一个新头寸,价值约为4.8万美元。36.32%的股票由机构投资者和对冲基金持有。
到达Acutus Medical警报:Acutus医疗类股上涨15.4%
纳斯达克:AFIB上周五开盘报1.5美元。Acutus Medical的一年低点为0.48美元,一年高位为2.49美元。该公司市值为4,268万美元,市盈率为-0.48,贝塔系数为0.64。该公司的债务权益比为0.59,流动比率为5.12,速动比率为4.33。该股的50日移动均线切入位在0.98美元,200日移动均线切入位在1.05美元。
Acutus Medical(纳斯达克:AFIB-GET评级)最近一次发布季度收益数据是在11月10日星期四。该公司公布了该季度每股收益(EPS)(0.72美元),比普遍预期的(0.83美元)高出0.11美元。该业务当季营收为364万美元,高于分析师预期的352万美元。Acutus Medical的净资产回报率为负100.62%,净利润率为负545.51%。卖方分析师预计,Acutus Medical本年度每股收益将达到2.84欧元。关于Acutus Medical
(获取评级)
Acutus Medical,Inc.是一家心律失常管理公司,设计、制造和销售一系列工具,用于在美国和国际上治疗各种心律失常的基于导管的消融程序。该公司的产品组合包括新型进入鞘、跨室间隔交叉工具、诊断和标测导管、常规和接触力消融导管、标测和成像控制台及附件,以及支持算法和软件程序。
阅读更多内容
- 免费获取StockNews.com关于Acutus Medical的研究报告(AFib)
- 市场回顾周-1/16-1/20
- Old Dominion是否表明Trucking正在踩刹车?
- 诺德斯特龙对零售业降价的担忧
- 埃克森美孚股票:在Buy Point附近
- 高股息率的必和必拓认为中国推动了23年的增长
接受《Acutus医学日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Acutus Medical和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧